Skip to content

All Lessons

Question & Answer Session (OMUFA: Understanding FY 2025 User Fees)

Question & Answer Session (OMUFA)

Question & Answer Session (OTGP)

Question & Answer Session (REMS Logic Model)

Question & Answer Session (Rx Promos)

Question & Answer Session 2 (ICH M12 Drug-Drug Interaction Studies)

Question & Answer Session and Closing Remarks (BsUFA III Science Pilot Program: Progress Update)

Question & Answer Session One (OSIS)

Question & Answer Session Two (OSIS)

Question & Answer Session (FDA Environmental Monitoring in Compounding)

Questions & Answer Session 1 (ICH M12 Drug-Drug Interaction Studies)

Reagan-Udall Foundation  

Recent Updates (Electronic Drug Registration and Listing 2024)

Recognized Consensus Standards: The Ultimate Weapon to Streamline Conformity Assessment and Advance Innovation

Registering Your Drug Manufacturing Establishment Using CDER Direct

Regulation of Medical Device Clinical Trials and Innovation in Clinical Evidence Generation

Regulatory Approach for Gene Therapies: Incorporating Human Somatic Genome Editing

Reimagining Clinical Research: The Transformation of Trial Design & Conduct 

REMS Logic Model in REMS Design, Implementation, and Evaluation

Request for Reconsideration – Overview and Experience from Bioequivalence Perspectives

Request For Reconsideration: Process Overview and Best Practices for FDA Evaluation

Requesting a Labeler Code from FDA

Rx Drug Promotion and the Clear, Conspicuous, and Neutral Final Rule

Safety Considerations in Clinical Drug Development

Safety Considerations in Clinical Drug Development

1 … 8 9 10 11 12 13
Share: